Novartis AG (NYSE:NVS) on Tuesday shared results from the VAYHIT2 Phase 3 trial of ianalumab plus eltrombopag in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids.In August, Novartis shared topline results from the VAYHIT2 trial.Ianalumab (9 mg/kg) plus e... Read more
Benzinga - Dec 09
Susan Monarez was let go from her position as director of the U.S. Centers for Disease Control and Prevention Wednesday. Read more
Wcpo - Aug 27
